SCHEMBL3392609

SCHEMBL3392609

CC1C(=O)CCCC1S(=O)(=O)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.55
ALDH1A1 P00352 5/20 0.44
GAA P10253 1/20 0.44
ACHE P22303 1/20 0.41
POLB P06746 1/20 0.40
TSHR P16473 1/20 0.38
MCL1 Q07820 1/20 0.38
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
MMP2 P08253 2/20 0.36
MMP9 P14780 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PARL Q9H300 1/20 0.35
HTR2A P28223 1/20 0.35
PSEN1 P49768 1/20 0.35
PSEN2 P49810 1/20 0.35
APH1B Q8WW43 1/20 0.35
NCSTN Q92542 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27721305 0.76 MAPT (0.49) MAPTALDH1A1ACHEKDM4EMEN1
SCHEMBL23720121 0.71 L3MBTL1 (0.46) MAPTALDH1A1ACHETSHRKDM4E
SCHEMBL13900254 0.71 MAPT (0.44) MAPTALDH1A1GAAACHEPOLB
SCHEMBL3391163 0.71 MAPT (0.44) MAPTALDH1A1GAAACHEPOLB
SCHEMBL11737793 0.70 MAPT (0.50) MAPTALDH1A1ACHEPOLBTSHR
SCHEMBL11369193 0.70 MAPT (0.97) MAPTALDH1A1GAATSHRMCL1
SCHEMBL24806685 0.69 MT-CO2 (0.43) ALDH1A1TSHRMCL1MEN1KMT2A
SCHEMBL22548166 0.69 ALDH1A1 (0.45) MAPTALDH1A1GAAACHEKDM4E
SCHEMBL22548427 0.69 MAPT (0.49) MAPTALDH1A1GAAACHEKDM4E
SCHEMBL24820969 0.69 MT-CO2 (0.43) ALDH1A1TSHRMCL1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1839653-B9 THERAPEUTIC AGENT FOR SENSORY DISORDERS MEIJI DAIRIES CORP (JP) 2010-12-22 EP disclosed
EP-2196200-A1 Cyclohexenone derivative for treating or preventing hypesthesia or hyperesthesia caused by diabetes Meiji Dairies Corporation (JP) 2010-06-16 EP disclosed
EP-1839653-B1 THERAPEUTIC AGENT FOR SENSORY DISORDERS MEIJI DAIRIES CORP (JP) 2010-06-09 EP disclosed
US-20090069442-A1 Therapeutic Agent for Sensory Abnormality MEIJI CO., LTD (JP) 2009-03-12 US disclosed
US-20080312336-A1 Preventive and/or Therapeutic Agent for Diabetic Vascular Disorder and Respiratory Disorder UNIVERSITE DE STRASBOURG (FR) 2008-12-18 US disclosed
EP-1839653-A1 THERAPEUTIC AGENT FOR SENSORY ABNORMALITY Meiji Dairies Corporation (JP) 2007-10-03 EP disclosed
US-7166642-B1 Use of cyclohexenone long-chain alcohol for treating neurodegenerative diseases MEIJI DAIRIES CORPORATION (JP) 2007-01-23 US disclosed
EP-1150667-B1 CYCLOHEXENONE LONG-CHAIN ALCOHOL FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS MEIJI DAIRIES CORP (JP) 2004-07-14 EP disclosed
EP-1003706-B1 CYCLOHEXENONE LONG-CHAIN ALCOHOL AND MEDICAMENT CONTAINING SAME MEIJI MILK PROD CO LTD (JP) 2003-03-05 EP disclosed
EP-1150667-A1 CYCLOHEXENONE LONG-CHAIN ALCOHOL FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS Meiji Dairies Corporation (JP) 2001-11-07 EP disclosed
US-6228893-B1 TREATING DEMENTIA MEIJI MILK PRODUCTS CO., LTD. (JP) 2001-05-08 US disclosed
WO-2000047199-A1 USE OF A CYCLOHEXENONE LONG-CHAIN ALCOHOL FOR TREATING NEURODEGENERATIVE DISEASES MEIJI DAIRIES CORPORATION (JP) 2000-08-17 WO disclosed
EP-1003706-A1 CYCLOHEXENONE LONG-CHAIN ALCOHOL AND MEDICAMENT CONTAINING SAME MEIJI MILK PRODUCTS COMPANY LIMITED (JP) 2000-05-31 EP disclosed
WO-1999008987-A1 CYCLOHEXENONE LONG-CHAIN ALCOHOL AND MEDICAMENT CONTAINING SAME MEIJI MILK PRODUCTS CO., LTD. (JP) 1999-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312336-A1 Preventive and/or Therapeutic Agent for Diabetic Vascular Disorder and Respiratory Disorder CPT1B, CHRM1, ADRA1D MAPT 4599/4885ALDH1A1 416/4885GAA 3427/4885
US-20090069442-A1 Therapeutic Agent for Sensory Abnormality PMP22, NGF, HRH1 MAPT 3594/4885ALDH1A1 200/4885GAA 4383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.